A Phase 1/1b Study of MPT-0118 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Solid Tumors
Study of MPT-0118 Alone or in Combination with Keytruda in Patients with Advanced or Metastatic Cancer
Sponsor: Monopteros Therapeutics, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT6182
U.S. Govt. ID: NCT04859777
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see if the investigational drug MPT-0118 is effective in treating people with cancer. This is the first time the study drug, MPT-0118, will be given to humans. MPT-0118 will be given alone (monotherapy) and in combination with Keytruda (pembrolizumab). Pembrolizumab is approved by the FDA to treat certain types of cancer. MPT-0118 and Pembrolizumab are called immunotherapies, which are designed to activate your immune system to try to kill cancer cells. Cancers may include bladder cancer, breast cancer, colon and rectal cancer, esophageal cancer, head and neck/oral cancers, kidney cancer, lung cancer, melanoma, pancreatic cancer, and prostate cancer.
This study is closed
Shaheer Khan, DO
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with metastatic or advanced cancer for which no approved therapy exists? Yes No
Have you previously received one prior line of therapy? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator